N/A
N=7,404
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
Immunization Status · Well Child Care Visit
Bottom Line
View on ClinicalTrials.gov: NCT01057888 ↗Enrolled (actual)
7,404
Serious AEs
—
Results posted
Nov 2012
Primary outcome: Primary: Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female)) — 143; 160; 100 participants — p=<0.05
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Autodialer (Other); Letters (Other)
- Age
- Pediatric, Adult · 11+ yrs
- Sex
- All
- Sponsor
- University of California, Los Angeles
- Primary completion
- Dec 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Fully Vaccinated (Tdap, Menactra and 3 Doses of HPV (if Female)) |
143; 160; 100 | <0.05 sig |
| PRIMARY Well Child Care Status |
908; 892; 768 | <0.01 sig |
Summary
The investigators will design and implement a randomized clinical trial to test, on a community-wide level, the effectiveness of managed care based tracking/reminder/recall on improving vaccination coverage among adolescents.
The investigators propose a randomized controlled trial to evaluate the effectiveness of reminder/recall for adolescents: 10,599 adolescents within the managed care organization (MCO) will be randomized into one of three arms: 1) mailed reminders, 2) autodialer telephone messages or 3) standard of care of their practice (no messages from the intervention).
Hypothesis 1: Reminder/recall will increase the receipt of immunizations and preventive services
Hypothesis 2: Telephone (autodialer) reminders will be more effective than mailed reminders
Hypothesis 3: The impact of reminders will be greatest for the most high-risk subgroups which have low baseline immunization rates.
Hypothesis 4: Mailed reminders will be more costly (and less effective) than telephone reminders.
Eligibility Criteria
Inclusion Criteria
- Member of the Monroe Plan for Medical Care (managed care organization)
- Patient of a participating practice
- Ages 10.75 to <18 years of age
Exclusion Criteria
- Member of the Monroe Plan for Medical care for less than 6 months
- ICD-9 diagnosis of 999.4 for anaphylactic reaction to a vaccine or its components.
- Encephalopathy within 7 days of a previous dose of a pertussis containing vaccine not attributable to another identifiable cause
- Guillain-Barre- ICD-9 code is 357.0
Data sourced from ClinicalTrials.gov (NCT01057888). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.